Dr Simó Schwartz Jr (1967th, Barcelona) is Director and Board member of CIBBIM-Nanomedicine, which fosters research on new biomedical advanced therapies and nanotechnology based applications for the clinical practice. In particular, advanced cell therapies, new biomaterials and drug delivery systems, image-based diagnostic systems, and preclinical validation of therapeutic conjugates and bio-nanosensors, mainly in the areas of oncology and rare diseases.
He is also member of the Science Advisory Board of the Vall d’Hebron Research Institute (VHIR) and member of the Science Advisory Board of the European Nanotechnology Characterization Laboratory (EUNCL). He also leads the “drug delivery and targeting group” at the CIBBIM-Nanomedicine. He holds 14 patents, most transferred to leading companies of the biotech and pharma sectors and coauthors more than 90 papers in high impact factor journals.
Dr Schwartz Jr is coordinator and collaborator of several research projects directly related with the obtention and validation of therapeutic drug delivery systems. Among them are international and EU projects involving SME’s in which animal models are being used for preclinical validation of newtherapies directed against tumor cells. Dr Schwartz Jr is also member of the Nanomedicine Spanish Platform (NanomedSpain) and of the “European Technology Platform for Nanomedicine”. His research group is also a group member of the “CIBER de Bioingeniería, Biomateriales y Nanomedicina” (CIBERBBN) of the Spanish Health Institute Carlos III (ISCIII) which gathers a total of 45 research groups of national excellence in the field of nanotechnology and nanomedicine.
Dr Schwartz Jr was the Nanomedicine Coordinador of CIBER-BBN at the national level and later appointed as Deputy Director and technology transfer coordinator. Dr Schwartz was also Co-founder and Science Advisor of ARGON Pharma SL (2008-2015), a Spin-Off company established at the Barcelona Science Park with the mission to develop new innovative therapies to provide solutions to unmet medical needs in the oncology field, and also to develop new technologies for drug delivery and diagnosis to improve current therapies. Dr Schwartz Jr is also member of the editorial Board of the Eur. J. Nanomedicine and until 2016 of Nanomedicine-NBM.
He also acted as Science Advisor of ORYZON GENOMICS, SOM BIOTECH and CELGENE, member of the Advisory Board of The Lundbeck Foundation Center of Excellence NanoCAN (Nanomedicine Research Center for Cancer Stem Cell Targeting Therapeutics), Southern Denmark University, and scientific referee for the European Commission, the Swedish Research Council and the FWF Austrian Science Foundation. He has been recently appointed as President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine.